trial

A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)

NCTId NCT05406440
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 53 (actual)
Sponsored by Merck Sharp & Dohme LLC
Primary completion 2023-02-24
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
53 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2022-07-12
Primary completion
2023-02-24
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Elpipodect

Sponsors

Merck Sharp & Dohme LLCLead Sponsor

Sites

3 total
Garden Grove, United StatesGlendale, United StatesMarlton, United States

Facts & assertions

4 sourced
Enrollment
53
Phase
PHASE1
Primary Completion Date
2023-02-24
Status
COMPLETED
relationships
The graph out of here
drug
Elpipodect
drug
lead_sponsor
Merck Sharp & Dohme LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication